UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000029727 |
|---|---|
| Receipt number | R000033967 |
| Scientific Title | Evaluation of cholesterol reduction effect by ingesting concentrated red malt |
| Date of disclosure of the study information | 2017/10/27 |
| Last modified on | 2018/12/26 18:57:40 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Evaluation of cholesterol reduction effect by ingesting concentrated red malt
Acronym
Evaluation of cholesterol reduction effect by ingesting supplement.
Scientific Title
Evaluation of cholesterol reduction effect by ingesting concentrated red malt
Scientific Title:Acronym
Evaluation of cholesterol reduction effect by ingesting supplement.
Region
| Japan |
Condition
Condition
Healthy adults
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
A placebo-controlled double-blind study was conducted to evaluate the effect of cholesterol reduction by ingesting concentrated red malt. We performed physical measurement, doctor's findings and evaluations, dietary advice, qualification judgment by doctor, health diary, height measurement, blood test, measurement of blood pressure and pulse, diet survey and lifestyle survey.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Blood test(LDL cholesterol)
Key secondary outcomes
Measurement of blood pressure and pulse
Blood test
Diet survey
Doctor's findings and evaluations
Dietary advice
Physical measurement
Health diary
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Test 2 capsules once once a day after dinner with water
Interventions/Control_2
Placebo 2 capsules once once a day after dinner with water
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 30 | years-old | <= |
Age-upper limit
| 59 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
1) Japanese males and females aged 30 to 59 years old at the time of acquiring consent on the first observation day (equal males and females)
2) Persons who have increased serum cholesterol
Key exclusion criteria
1) Persons who are taking medications (lipid-lowering drugs, etc.) that are likely to affect the test results
2) Persons routinely taking health foods (supplements with cholesterol-reducing effect, etc.) that are likely to affect the test results
3) Alcohol addiction
4) Persons who are likely to have allergic symptoms depending on the test article component
5) Participating in other clinical trials
6) Persons who have a history of serious liver disorder, kidney disorder, heart disease
7) Persons who have a history of hepatitis or who are currently suffering from hepatitis
8) Persons with serious anemia
9) Persons who are judged inappropriate to participate the study by the supervising doctor (When recognizing the fact that it is determined to be ineligible during the course of the test, it is excluded from the analysis subject. Note that inspection items that are not screening criteria are not an exclusion criterion from screening.)
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Takashi Koikeda |
Organization
Shiba Palace Clinic
Division name
Chair
Zip code
Address
6F DaiwaA Hamamatucho Bld., 1-9-10 Hamamatsucho, Minato-ku, Tokyo, 105-0013, Japan
TEL
03-5408-1590
jimukyoku@mail.souken-r.com
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Ko Masuda |
Organization
SOUKEN Co., Ltd
Division name
Management Division
Zip code
Address
3F DaiwaA Hamamatucho Bld., 1-9-10 Hamamatsucho, Minato-ku, Tokyo, 105-0013, Japan
TEL
03-5408-1555
Homepage URL
k_masuda@mail.souken-r.com
Sponsor or person
Institute
Shiba Palace Clinic
Institute
Department
Personal name
Funding Source
Organization
DHC Corporation.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 10 | Month | 27 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2017 | Year | 09 | Month | 04 | Day |
Date of IRB
Anticipated trial start date
| 2017 | Year | 10 | Month | 18 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2017 | Year | 10 | Month | 26 | Day |
Last modified on
| 2018 | Year | 12 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033967
